{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:14:21Z","timestamp":1779290061839,"version":"3.51.4"},"publisher-location":"Chichester, UK","reference-count":31,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003831","type":"reference-entry","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T22:14:00Z","timestamp":1069452840000},"source":"Crossref","is-referenced-by-count":14,"title":["Celecoxib for rheumatoid arthritis"],"prefix":"10.1002","author":[{"given":"Sarah E","family":"Garner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dogan","family":"Fidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth R","family":"Frankish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Judd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanveer","family":"Towheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,10,21]]},"reference":[{"issue":"9196","key":"10.1002\/14651858.CD003831-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","article-title":"Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison","volume":"354","author":"Emery","year":"1999","journal-title":"Lancet"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003831-BIB2|cit2","first-page":"Abstract 1699","article-title":"Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis [abstract]","volume":"41","author":"Geis","year":"1998","journal-title":"Arthritis & Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD003831-BIB3|cit3","first-page":"2606-abstract 1","article-title":"Serial endoscopies confirm lower incidence of gastroduodenal ulceration with celecoxib as compared to naproxen [abstract]","volume":"94","author":"Burr","year":"1999","journal-title":"American journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003831-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1572-0241.2001.03740.x","article-title":"Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase -2 inhibitor, compared to naproxen in patients with arthritis","volume":"96","author":"Goldstein","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD003831-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD003831-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J","article-title":"Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects","volume":"41","author":"Simon","year":"1998","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003831-BIB7|cit7","first-page":"Abstract 1990","article-title":"Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis [abstract]","volume":"41","author":"Geis","year":"1998","journal-title":"Arthritis & Rheumatism"},{"issue":"20","key":"10.1002\/14651858.CD003831-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","article-title":"Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial [see comments]","volume":"282","author":"Simon","year":"1999","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD003831-BIB9|cit9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/1529-0131(200004)13:2<112::AID-ANR5>3.0.CO;2-L","article-title":"Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib","volume":"13","author":"Zhao","year":"2000","journal-title":"Arthritis Care & Research"},{"issue":"suppl 9","key":"10.1002\/14651858.CD003831-BIB10|cit10","first-page":"Abstract 373","article-title":"A pilot endoscopic study of the gastroduodenal effects of SC-58635, a COX-2 selective inhibitor. [abstract]","volume":"40","author":"Lanza","year":"1997","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD003831-BIB11|cit11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/00912700022008766","article-title":"Effects of celecoxib, a novel cyclooxygenase-2 inhibitor on platelet function in healthy adults: a randomized, controlled trial","volume":"40","author":"Leese","year":"2000","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD003831-BIB12|cit12","first-page":"9","article-title":"Outcome of specific COX-2 inhibition in rheumatoid arthritis","volume":"24 Suppl 49","author":"Lipsky PE","year":"1997","journal-title":"J-Rheumatol"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003831-BIB13|cit13","first-page":"Abstract 1352","article-title":"Early experience with selective COX-2 inhibitors; safety profile in over 340,000 patient years of use [abstract]","volume":"42","author":"Singh","year":"1999","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD003831-BIB14|cit14","unstructured":"Rosenberger   L Revised integrated clinical and statistical report for a pilot dose-ranging study to evaluate the safety and efficacy of SC-58635 40mg, 100mg nad 200mg bid versus placebo in treating the signs and symptoms of osteoarthritis. [Searle Study 13 - unpublished]"},{"key":"10.1002\/14651858.CD003831-BIB15|cit15","volume-title":"British National Formulary","author":"BNF","year":"2002"},{"key":"10.1002\/14651858.CD003831-BIB16|cit16","article-title":"Advisory Commitee Briefing Document: Review of Celecoxib Long-Term Arthritis Safety Study (CLASS)","author":"FDA Briefing","journal-title":"http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b1.htm"},{"key":"10.1002\/14651858.CD003831-BIB17|cit17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1002\/14651858.CD003831-BIB18|cit18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1002\/14651858.CD003831-BIB19|cit19","article-title":"Rofecoxib in the treatment of rheumatoid arthritis","author":"Garner","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003831-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised controlled trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD003831-BIB21|cit21","unstructured":"Hong Laura   Lu Statistical reviewer briefing document for the Arthritis Advisory Committee http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b1_04_stats.doc 2000"},{"key":"10.1002\/14651858.CD003831-BIB22|cit22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3111\/199902045055","article-title":"Cost of NSAID adverse events in the UK NHS","volume":"2","author":"Moore","year":"1999","journal-title":"Journal of Medical Economics"},{"key":"10.1002\/14651858.CD003831-BIB23|cit23","first-page":"526","article-title":"Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials","author":"OMERACT","year":"1993"},{"issue":"8","key":"10.1002\/14651858.CD003831-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/1529-0131(199908)42:8<1572::AID-ANR2>3.0.CO;2-G","article-title":"ACR20: clinical or statistical significance?","volume":"42","author":"Pincus","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1002\/14651858.CD003831-BIB25|cit25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003831-BIB26|cit26","first-page":"811","article-title":"Epidemiology and rheumatic diseases","volume-title":"Oxford Textbook of Rheumatology","author":"Silman","year":"1998"},{"issue":"47","key":"10.1002\/14651858.CD003831-BIB27|cit27","first-page":"3","article-title":"Low dose etodolac in rheumatoid arthritis: a review of early studies","volume":"Supplement","author":"Spencer-Green","year":"1997","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD003831-BIB28|cit28","article-title":"Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip.","author":"Towheed","year":"2000","journal-title":"Cochrane Library"},{"key":"10.1002\/14651858.CD003831-BIB29|cit29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annual Review of Pharmacology & Toxicology"},{"issue":"2","key":"10.1002\/14651858.CD003831-BIB30|cit30","article-title":"Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee","author":"Watson","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"24","key":"10.1002\/14651858.CD003831-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Medical progress: gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"NEJM"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003831.pub2","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000},"record-id":"30937"},{"DOI":"10.1002\/14651858.cd003831.pub2","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003831\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:26:18Z","timestamp":1628544378000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003831"}},"subtitle":[],"editor":[{"given":"Sarah E","family":"Garner","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2002,10,21]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003831","relation":{"withdrawal":[{"id-type":"doi","id":"10.1002\/14651858.CD003831.pub2","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2002,10,21]]}}}